Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Belatacept in De Novo Renal Transplant
NCT00578448Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2008
- Primary completion
- Mar 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of belatacept in kidney transplant rejection, sponsored by Bristol Myers Squibb. Primary endpoints: Mean Belatacept Serum Concentrations Between Weeks 12 and 16 at 16 weeks, Maximum Observed Serum Concentration at 16 weeks and 5 more. Started Mar 2008; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00578448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578448.